CVS Health to Terminate SilverScript Choice PDP in 13 Regions for 2027
CVS Health is terminating its SilverScript Choice stand-alone prescription drug plan in 13 regions for the 2027 coverage year, impacting approximately 950,000 enrollees.
Stocks · News reference
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Analysts highlight high-yield healthcare stocks Perrigo (7.09%), Pfizer (5.65%) and CVS Health (2.82%), with updated ratings and news.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CVS Health Reports Worsening Shortages of Estradiol Injections
CVS Health stated that manufacturers have struggled to supply certain strengths of estradiol injections, with the situation deteriorating in recent weeks.
US Department of Labor to Require PBM Transparency Disclosures
The U.S. Department of Labor is expected to introduce new regulations requiring Pharmacy Benefit Managers (PBMs) to disclose detailed information regarding their fees and revenue sources to employer clients.
CVS Health Engages in Medicare Negotiations to Expand Pharmacist Roles and GLP-1 Access
CVS Health is in discussions with Medicare to broaden the scope of pharmacist-led chronic disease management and improve patient access to high-cost GLP-1 medications.
Pfizer Announces Corporate Restructuring and Clinical Trial Adjustments
Pfizer has initiated a corporate restructuring and workforce reduction program while simultaneously adjusting its clinical trial pipeline.
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight
The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.